We develop, manufacture and market bone density assessment and monitoring solutions. In particular, we lead the market with advanced ultrasound technology and devices that enable physicians to provide early assessment, diagnosis and monitoring of osteoporosis and to assess bone age. There are already thousands of our devices in use in clinics, physician offices, HMO’s, research centers, hospitals, check-up centers and pharmacies around the world.
Our bone density assessment line of devices is based on our patented Omnipath™ axial transmission technology, a quantitative ultrasound technology that has been proven as an effective screening tool for osteoporosis which improves HEDIS measures, allowing reaching 5-stars rating for Hedis OMW. Measurement using our Omnisense and MiniOmni is reimbursed in the USA and other countries.
Addressing a Widespread Health Problem – Osteoporosis
Osteoporosis is a progressive systemic skeletal disease that is accepted as a major public health problem, with huge associated cost. Osteoporosis-related fractures increase dramatically with age and they often cause rapid deterioration in health, resulting in death. According to the International Osteoporosis Foundation (IOF), hundreds of millions of people worldwide are affected by osteoporosis – about 80% are women.
Osteoporosis cannot be reversed. However, it can be effectively managed by early diagnosis of bone mass loss and by prevention of further loss. Although early assessment is key, the IOF estimates that more than 70% of the people at risk of osteoporosis have never been diagnosed or screened – signifying a pressing need for easy, cost-effective and safe early assessment tools.
Pioneering Early Assessment of Bone density
As the first – and currently only – devices that enable ultrasound-based, multi-site measurement for early assessment and monitoring of osteoporosis, our Sunlight product line overcome the cost and radiation exposure-related challenges of Dual X-ray Absorption technology (DXA). High accuracy, small size, ease of use, reliability, excellent affordability, and radiation-free operation mean that our systems can easily and safely be used in any doctor’s office, clinic, HMO or retail venue such as pharmacies and checkup centers.
We offer a range of bone density assessment solutions, all based on our proven Omnipath technology.
Sunlight Omnisense™ 9000 is designed for accurate, quick and patient-friendly assessment of bone density and monitoring of osteoporosis.
Sunlight Omnisense™ 8000 offers the same extensive functionality as the 9000 but is portable.
Sunlight MiniOmni™ is the world’s first portable, multi-site bone density assessment device specifically designed for osteoporosis screening and monitoring anywhere, anytime. The exceptionally small and affordable unit plugs via USB connectivity into Windows™ 7/8-based laptop or desktop computer.
We also offer unique solutions that cover the pediatric population:
- Sunlight BonAge is an innovative ultrasound device for accurate bone age evaluation, used for assessing pediatric skeletal development and growth. *
- Sunlight Pediatric software allows an accurate bone density assessment of children aged 0-18 years.
- Sunlight PREMIER software enables safe and accurate bone density assessment in premature babies.
* Please Note: The application/device has not yet been approved by the US FDA and is not available for sale in the USA.
Solid Company with a Strong Growth Path
The Sunlight product line and brand is owned by BeamMed Ltd. – a company wholly focused on bone health. BeamMed was founded in 2004 and is headquartered in Israel. It purchased the Sunlight ultrasound division and IP rights in 2006, and has since significantly expanded the Sunlight installed base and extend the product line with new devices. Privately owned, BeamMed is led by a seasoned management team and is backed by strong investment groups, providing a solid financial base for its development road map and global growth plans.